Peijia Medical (HKSE:09996) ROCE % : -5.47% (As of Jun. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Peijia Medical ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Peijia Medical's annualized ROCE % for the quarter that ended in Jun. 2024 was -5.47%.

Peijia Medical ROCE % Historical Data

The historical data trend for Peijia Medical's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Peijia Medical ROCE % Chart

Peijia Medical Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-110.45

-114.43

-19.82

-13.03

-14.73

Peijia Medical Semi-Annual Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
ROCE %	Get a 7-Day Free Trial							-5.88	-20.78	-15.47	-13.88	-5.47

Peijia Medical ROCE % Calculation

Peijia Medical's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-428.021	/	( ( (3703.555 - 645.487)	+	(2922.538 - 168.714) )	/ 2 )
	=	-428.021	/	( (3058.068	+	2753.824)	/ 2 )
	=	-428.021	/	2905.946
	=	-14.73 %

Peijia Medical's ROCE % of for the quarter that ended in Jun. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Jun. 2024 )		(Q: Dec. 2023 )		(Q: Jun. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Jun. 2024 )		(Q: Dec. 2023 )		(Q: Jun. 2024 )
	=	-147.158	/	( ( (2922.538 - 168.714)	+	(2814.057 - 187.786) )	/ 2 )
	=	-147.158	/	( ( 2753.824	+	2626.271 )	/ 2 )
	=	-147.158	/	2690.0475
	=	-5.47 %

(1) Note: The EBIT data used here is two times the semi-annual (Jun. 2024) EBIT data.

Peijia Medical (HKSE:09996) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Peijia Medical ROCE % Related Terms

Thank you for viewing the detailed overview of Peijia Medical's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Peijia Medical Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Peijia Medical Ltd (HKSE:09996) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

4WO:Germany

Address

8 Zhongtian Street, Suzhou Industrial Park, Jiangsu Province, Suzhou, CHN

Website

https://www.peijiamedical.com

Peijia Medical Ltd is focused on the interventional procedural, transcatheter valve therapeutic, and the neurointerventional procedural medical device market in China. The company's product candidates include Transcatheter Aortic Valve Replacement products, Transcatheter Mitral Valve Replacement/Transcatheter Tricuspid Valve Replacement products, Ancillary products, Neurointerventional products, and its product pipeline consists of transcatheter valve therapeutic and neurointerventional products and product candidates. Its operating segments are Transcatheter Valve Therapeutic Business and Neurointerventional Business.

Executives

Pandanus Partners L.p.	2201 Interest of corporation controlled by you
Pandanus Associates Inc.	2201 Interest of corporation controlled by you
Fil Limited	2201 Interest of corporation controlled by you
Hh Sum-xxiv Holdings Limited	2101 Beneficial owner
Hillhouse Investment Management, Ltd.	2102 Investment manager
Hh Imv Holdings, L.p.	2201 Interest of corporation controlled by you
Hillhouse Fund Iv, L.p.	2201 Interest of corporation controlled by you
Zhang Ping Ye	2103 Interests held jointly with another person
Jinnius Drive Trust	2103 Interests held jointly with another person
Xinyue International Limited	2103 Interests held jointly with another person
Ye Hong	2103 Interests held jointly with another person
Hanlindale Trust	2103 Interests held jointly with another person
Zhang Yi	2301 Trustee
Lav Asset Management (hong Kong) Limited	2102 Investment manager
Shi Yi	2201 Interest of corporation controlled by you

Peijia Medical Headlines

No Headlines